A. Field
The disclosure relates generally to the fields of medicine, diagnostics, therapy, and imaging. More particularly, it relates to the synthesis and use of pH-sensitive nanoparticles.
B. Related Art
Metal nanoparticles (NPs) generally do not fluoresce because of their large density of states; as a result, conjugation of organic dyes to non-luminescent metal NPs is essential for visualizing them in fluorescence imaging systems (Xie et al., 2010; Palner et al., 2015; Hu and Gao, 2010). For instance, Chan et al. conjugated organic dyes such as Cyto633 to different sized non-luminescent gold NPs (AuNPs), so that these AuNPs can be readily monitored in real time in vivo (Chou and Chan, 2012). In addition, due to surface plasmon absorption of metal nanoparticles, Raman scattering of organic dyes was significantly enhanced and has also found broad applications in bioimaging and sensing.
Different from conventional non-luminescent metal NPs, a new class of metal NPs that can give intrinsic fluorescence without being labeled with organic dyes has also emerged in the past decade (Zheng et al., 2003; Zheng et al., 2004; Zheng et al., 2007). By tuning particle size, crystallinity, surface ligands and valance states, the inventors and others were able to create a large number of luminescent metal NPs with tunable emission ranging from UV to NIR (Zhou et al., 2012; Zhou et al., 2011; Zheng et al., 2012). Complementary to dye-labeled non-luminescent metal NPs, metal NPs with intrinsic emissions have also found many applications in imaging and sensing. For instance, red-emitting AuNPs have been used to detect small metal ions, toxin and reactive oxygen species (Wei et al., 2010; Chen et al., 2013). More recent studies show that NIR-emitting AuNPs can serve as a new class of renal clearable contrast agents for rapid tumor diagnosis and kidney functional imaging (Liu et al., 2013; Yu et al., 2015; Yu and Zheng, 2015). While the emergence of these luminescent metal NPs suggests that organic dyes might no longer be necessary for detecting metal NPs in the fluorescence imaging systems, rational integration of organic dyes with ultrasmall metal nanoparticles can lead to a new class of nanosensors that can exhibit strong responses to external chemical or physical changes such as pH, glutathione, cysteine and light irradiation.
In accordance with the present disclosure, there is provided a composition comprising a nanoparticle, wherein the surface of the nanoparticle is conjugated with (a) a charged ligand susceptible to protonation or deprotonation by pH change and (b) a dye that is pH-insensitive when not conjugated with the nanoparticle. The nanoparticle may be a gold nanoparticle (i.e., only gold, predominantly gold, or partially gold). The nanoparticle may be about 0.5 nm to 10 nm in diameter, or may be about 1 nm to 5 nm in diameter, may be below 5 nm in diameter, below or less than 3 nm in diameter, below 1 nm in diameter, and optionally with a lower limit diameter of 0.5 nm, 0.6 nm, 0.7 nm, 0.8 nm, 0.9 nm or 1.0 nm. The nanoparticle metal may also comprise, consist of or consist essentially of silver, copper, platinum, or carbon. The nanoparticle may be luminescent, and may emit at blue to infrared wavelengths.
The nanoparticle may provide a ratiometric comparison of emissions from said dye and the luminescence. The charged ligand may be glutathione, cysteine, cysteine-glycine or cysteine-glutamate, or any other ligand that is differentially protonated across various pHs. The charged ligand may be capable of binding to at least one cellular component. The gold nanoparticle may comprise a second ligand capable of binding to at least one cellular component. The cellular component may be a tumor marker. The blood residence half-time of the nanoparticle after administration of the gold nanoparticle to a subject may be from about 2 hours to about 25 hours. The pH insensitive dye may be tetramethyl rhodamine (TAMRA), an Alexa Fluor Dyes, boron-dipyrromethene, or Rhodamine 6G. The composition may comprise two or more pH insensitive dye molecules. The two or more pH insensitive dye molecules may be different or the two or more pH insensitive dye molecules may be the same. The nanoparticle may be sensitive to a pH from about 5 to about 11, from about 6 to about 10, from about 7 to about 9, or at about pH 5, 6, 7, 8, 9, 10 or 11.
In another embodiment, there is provided a method for detecting pH of an environment comprising the steps of (a) contacting the environment with a composition comprising a nanoparticle as set out above; and (b) monitoring the emission from the nanoparticle by optical imaging, microscopic imaging or combinations thereof. The optical imaging technique may be fluorescence imaging or near infrared imaging. The environment may be in a living subject. The composition may be administered to said living subject orally, intravenously, nasally, subcutaneously, intramuscularly or transdermally. The monitoring may occur over time and detects a change in pH of the environment.
In yet another embodiment, there is provided a composition comprising a noble metal nanoparticle, wherein the surface of the nanoparticle is conjugated with (a) a charged ligand susceptible to protonation or deprotonation by pH change and (b) a pH-sensitive dye, wherein said pH-sensitive dye is more pH sensitive when conjugated to said nanoparticle than when not conjugated with the nanoparticle. The may be nanoparticle is about 0.5 nm to 10 nm in diameter, or about 1 nm to 5 nm in diameter. The nanoparticle may be luminescent, may be gold, and/or may emit at blue to infrared wavelengths. The nanoparticle may provide a ratiometric comparison of emissions from said dye and the luminescence. The charged ligand may be glutathione, cysteine, cysteine-glycine, cysteine-glutamate or any other ligand that is differentially protonated across various pHs. The charged ligand may also be capable of binding to at least one cellular component, such as a tumor marker. The nanoparticle may also comprise a second ligand capable of binding to at least one cellular component. The cellular component may be a tumor marker. The nanoparticle metal may also comprise, consist of or consist essentially of silver, copper, platinum, or carbon.
The blood residence half-time of the nanoparticle after administration of the gold nanoparticle to a subject may be from about 2 hours to about 25 hours. The pH sensitive dye may be 2-fold, 3-fold, 4-fold, 5-fold or 10-fold more sensitive when conjugated to gold nanoparticle as compared to its unconjugated state. The pH sensitive dye may be (6)-carboxyfluorescein, 7-hydroxycourmarin-3-carboxylic acid, rhodamine B octadecyl ester perchlorate, 2′,7′-Bis(3-carboxypropyl)-5(6)-carboxyfluorescein (BCECF), 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (HPTS). The nanoparticle may be sensitive to a pH from about 5 to about 11, from about 6 to about 10, from about 7 to about 9, or at about pH 5, 6, 7, 8, 9, 10 or 11. The nanoparticle may be 0.5-10 nm in diameter, or 1 nm to 5 nm in diameter. The nanoparticle may contain 2 dye particles.
In still yet another embodiment, there is provided a method for detecting pH of an environment comprising the steps of (a) contacting the environment with a composition comprising a nanoparticle as set out above; and (b) monitoring the emission from the nanoparticle by optical imaging, microscopic imaging or combinations thereof. The optical imaging technique may be fluorescence imaging or near infrared imaging. The environment may be in a living subject. The composition may be administered to said living subject orally, intravenously, nasally, subcutaneously, intramuscularly or transdermally. The monitoring may occur over time and detects a change in pH of the environment.
In yet another aspect, the present disclosure provides methods for determining the presence of a thiolated compound in an environment comprising the steps of:
(a) contacting the environment with a composition comprising a nanoparticle described herein; and
(b) monitoring the emission from the nanoparticle by optical imaging, microscopic imaging, or combinations thereof, wherein a change in the emission is associated with the presence of a thiolated compound.
The optical imaging technique may be fluorescence imaging or near infrared imaging. In some embodiments, the environment is in a living subject. The composition may be administered to said living subject orally, intravenously, nasally, subcutaneously, intramuscularly or transdermally. In some embodiments, monitoring occurs over time and detects a change in the concentration of the thiolated compound in the environment. In some embodiments, the thiolated compound is glutathione or cysteine.
Also provided is a method for detecting pH in a tumor environment in a subject comprising administering to the subject cell an effective amount of a composition as described above.
The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The word “about” means plus or minus 5% of the stated number.
It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. Other objects, features and advantages of the present disclosure will become apparent from the following detailed description.
It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
Here, the inventors report conjugating a pH insensitive dye, 581 nm emitting TAMRA (
Additionally, these nanoparticles may include other pH sensitive surface ligands such as cysteine, cysteine-glutamate, and cysteine-glycine which may be used to synthesize the luminescent nanoparticles and the fabricated organic dye conjugated nanoparticles, which can result in distinct pH-dependent emissions.
In addition to the ability of these nanoparticles to sense pH, the nanoparticles may be used to sense glutathione, cysteine, and other thiolated compounds in the physiological environment.
These and other aspects of the disclosure are set out in detail below.
The claimed disclosure provides nanoparticle compositions comprising a gold nanoparticle, methods for preparing the nanoparticle compositions and methods of using the nanoparticle compositions. As used herein, the term “nanoparticle” refers to an association of 2-1000 atoms of a metal, in this case gold. Nanoparticles may have diameters in the range of about 0.5 to about 5 nm. As used herein, diameter refers to the core size of the metal core. The metal core may be a gold core. In other preferred embodiments, the nanoparticles comprise approximately 2-1000, approximately 2-500, approximately 2-250, approximately 2-100, approximately 2-25 atoms, or approximately 2-10 atoms.
The nanoparticles may also be luminescent and emit one, two or more different colored emissions ranging from blue to IR.
The properties of the nanoparticles enable excretion through the kidneys, as well as selective uptake and retention in tumors compared with normal tissues. This, along with the lack of in vivo toxicity, has resulted in a composition that is promising for translation to the clinic. In some embodiments of the present disclosure, greater than 30%, 40%, 50%, 60%, 70%, 80% or 90% of the nanoparticles may be eliminated from the body through the urinary system.
In certain embodiments, the surface of the nanoparticle is coated with a ligand. In certain embodiments of the disclosure, the anti-fouling ligand is a zwitterionic material such as sulfobetaine methacrylate (SBMA), carboxybetaine methacrylate (CBMA), poly(carboxybetaine acrylamide) (polyCBAA) or a mixed charge material. In certain embodiments of the disclosure the ligand is glutathione, cysteine, cysteine-glycine, cysteine-glutamate, and other thiolated surface ligands which can be protonated at different pHs.
In certain embodiments, the ligand (or a further ligand) is capable of binding to at least one cellular component. The cellular component may be associated with specific cell types or having elevated levels in specific cell types, such as cancer cells or cells specific to particular tissues and organs. Accordingly, the nanoparticle can target a specific cell type, and/or provides a targeted delivery for the treatment and diagnosis of a disease. As used herein, the term “ligand” refers to a molecule or entity that can be used to identify, detect, target, monitor, or modify a physical state or condition, such as a disease state or condition. For example, a ligand may be used to detect the presence or absence of a particular receptor, expression level of a particular receptor, or metabolic levels of a particular receptor. The ligand can be, for example, a peptide, a protein, a protein fragment, a peptide hormone, a sugar (i.e., lectins), a biopolymer, a synthetic polymer, an antigen, an antibody, an antibody fragment (e.g., Fab, nanobodies), an aptamer, a virus or viral component, a receptor, a hapten, an enzyme, a hormone, a chemical compound, a pathogen, an aromatic compound, a microorganism or a component thereof, a toxin, a surface modifier, such as a surfactant to alter the surface properties or histocompatability of the nanoparticle or of an analyte when a nanoparticle associates therewith, and combinations thereof.
Other metals such as silver, copper, and platinum and even carbon, etc., may be used to generate nanoparticles for use in accordance with the present disclosure, including in ultrasmall and/or luminescent nanoparticles.
The nanoparticles may be synthesized as has been reported in 8a. This approach may be used to synthesize nanoparticles such as an 815 nm GSAu-NPs, 650 nm cysteine-glycine coated gold nanoparticle (Cys-Gly-AuNPs), and 600 nm/800 nm cysteine-glutamate gold nanoparticles (Cys-Glu-AuNPs). Additionally, procedures such as thermal decomposition at room temperature may be used to prepare the nanoparticles such as 650 nm emitting cysteine-AuNPs (Cys-AuNPs).
Additionally, the near IR emitting GS-AuNPs may be prepared using the following protocol: 150 μL of 1 M HAuCl4 solution was added to 50 mL of 2.4 mM glutathione solution in a 100 mL three-necked flask while stirring vigorously. The mixture was then heated with an oil bath at 90° C. for 35 min. The resulting solution was cooled to room temperature and centrifuged at 21,000 g for 1 min to remove large aggregates. The NPs were precipitated out of the supernatant using the following steps: adding 1 M NaOH to the supernatant to adjust the pH to approximately 3; adding ethanol solution (2:1, Vwater/Vethanol); and centrifuging at 4,000 g for 5 min. The precipitates were suspended in 300 μL PBS buffer, and 1 M NaOH was added to adjust the pH to approximately 7. The PBS solution was centrifuged at 21,000 g for 1 min. The supernatant was the final product. For the animal studies, the GS-AuNPs were further purified using a NAP-5 column (Sephadex G-25 DNA Grade gravity columns) in phosphate buffer saline (PBS). The protocol to synthesize NIR-emitting GS-AuNPs is based upon the protocol described in Liu et al., 2013, which is incorporated herein by reference.
These noble metal nanoparticles may be prepared using noble metals or noble metal salts and then incubated with a dye in a buffer. In some embodiments, the dye has an activated group which reacts with one of the metal atoms on the surface of the nanoparticle such as a thiol group reacting with a metal ion. In some embodiments, the ratio of the noble metal nanoparticle to the dye is about 1:100 to about 1:10,000. In some embodiments, the concentration of the nanoparticle is less than 100 nM. In some embodiments, the concentration of the dye is greater than 10 nM. In some embodiments, these components are dissolved in a pH buffer. The incubation of the dye with the nanoparticle may be carried out in the dark. Without wishing to be bound by any theory, it is believed that carrying out the reaction in the dark reduces the photobleaching the dye. After incubating these components together for a period of time from about 1 hour to about 72 hours, the excess dye is removed by dialysis or chromatography. In some embodiments, the excess dye is removed via column chromatography such as with a size exclusion or Sephadex® column. The attachment of the dye may be confirmed using gel electrophoresis or other appropriate spectroscopic techniques.
The present disclosure provides for improved imaging compositions that create or increase pH sensitivity in pH insensitive and pH sensitive dyes, respectively. In some embodiments, the nanoparticles comprises two or more dyes, such as 2-100, 2-50, or 2-20 dyes per nanoparticle. A non-limiting discussion of such dyes is provided below.
A. pH Insensitive
pH insensitive dyes include tetramethyl-rhodamine (TAMRA), Alexa Fluor Dyes, boron-dipyrromethene (BODIPY), and several other dyes which show little response to the pH of the local environment.
B. pH Sensitive Dyes and Weakly pH Sensitive Dyes
pH sensitive/weakly sensitive dyes include fluorescein, 5(6)-carboxyfluorescein, 7-hydroxycourmarin-3-carboxylic acid, rhodamine B octadecyl ester perchlorate, 2′,7′-Bis(3-carboxypropyl)-5(6)-carboxyfluorescein (BCECF), 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (HPTS), Acid Blue 113, Brilliant Yellow, Zinc 5,10,15,20-tetra(4-pyridyl)-21H, 23H-porphine, Protoporphyrin IX di sodium salt, 5,10,15,20-tetraphenyl-21H,23H-porphine zinc low chlorin.
The present disclosure further encompasses methods of using the gold nanoparticles in order to study pH of an environment or the presence of other biologically important molecules such as glutathione and cysteine. The disclosure provides for a method of detecting pH, monitoring pH change, or the presence of glutathione or cysteine in an environment over a period of time. In a particular embodiment, the environment is located in a living subject, such as a mammal, including humans. The environment may also be a site of disease, such as tumor environments, inflammation sites, and infection sites (e.g., bladder or kidney) where local pH or the concentration of glutathione or cysteine is changed dramatically.
After administration of the nanoparticle to a subject, the blood residence half-time of the nanoparticles may range from about 2 hours to about 25 hours, from about 3 hours to about 20 hours, from about 3 hours to about 15 hours, from about 4 hours to about 10 hours, or from about 5 hours to about 6 hours. Longer blood residence half-time means longer circulation, which allows more nanoparticles to accumulate at the target site in vivo. Blood residence half-time may be evaluated as follows. The nanoparticles are first administered to a subject (e.g., a mouse, a miniswine or a human). At various time points post administration, blood samples are taken to measure nanoparticle concentrations through suitable methods.
An embodiment of the claimed disclosure is directed to a gold nanoparticle that is renal clearable. In certain embodiments of the disclosure, the compositions demonstrate greater than 30% renal clearance within 48 hours of administration.
Imaging techniques employed with the gold nanoparticles described herein include optical imaging, microscopic imaging, X-ray imaging, CT imaging, SPECT imaging, PET imaging, and combinations thereof.
In an embodiment of the disclosure, a therapeutic agent may also be attached to the nanoparticle. The therapeutic agent is selected from the group consisting of antibiotics, antimicrobials, antiproliferatives, antineoplastics, antioxidants, endothelial cell growth factors, thrombin inhibitors, immunosuppressants, anti-platelet aggregation agents, collagen synthesis inhibitors, therapeutic antibodies, nitric oxide donors, antisense oligonucleotides, wound healing agents, therapeutic gene transfer constructs, extracellular matrix components, vasodialators, thrombolytics, antimetabolites, growth factor agonists, antimitotics, statin, steroids, steroidal and nonsteroidal anti-inflammatory agents, angiotensin converting enzyme (ACE) inhibitors, free radical scavengers, PPAR-γ agonists, small interfering RNA (siRNA), microRNA, and anti-cancer chemotherapeutic agents. As such, a further embodiment of the disclosure is directed to a method for targeting/treating a disease site, such as a tumor, comprising administering an effective amount of a gold nanoparticle composition as described above conjugated with at least one therapeutic agent.
The following examples are included to demonstrate preferred embodiments. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of embodiments, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.
Materials and Equipment. All chemicals were purchased from Fisher Scientific and were used as received without further purification. Transmission electron microscopy (TEM) images of the RG-AuNPs were obtained using a JEOL 2100 transmission electron microscope with a 200 kV accelerating voltage. Hydrodynamic diameters (HDs) of the samples in the aqueous solution were analyzed using a Brookhaven 90Plus Dynamic Light Scattering (DLS) Particle Size Analyzer. Zeta potentials of the samples were analyzed by a Brookhaven ZetaPALS zeta potential analyzer. Fluorescence lifetimes were measured with a PTI time resolved fluorescence lifetime spectrometer. pH was measured by a Accumet AB15 pH meter and a Accuphast microprobe electrode. Absorption spectra were taken using a Varian 50 Bio UV-Vis spectrophotometer.
Synthesis method and characterization—Synthesis of TG-AuNPs. To conjugate organic dyes including TAMRA and Fluorescein to GS-AuNPs, Cys-AuNPs, Cysgly-AuNPs, NHS- TAMRA solution was added to GS-AuNPs in phosphate buffered saline (PBS) solution in a vial. The mixture was shaken at room temperature in the dark for 24 h. The NHS ester group of TAMRA reacted with the amines on glutathione to form a stable amide bond. After the reaction was completed, the mixture was further purified to remove the unreacted TAMRA molecules.
Quantification of the number of TAMRA per nanoparticle. To quantify the number of dye molecules per individual AuNP, a standard calibration curve of TAMRA absorbance as a function of TAMRA concentration was made in the range of Beer's law. The TG-AuNPs solution was treated with 10 mM glutathione solution for 24 h. Then, the amount of 5(6)-TAMRA in the solution was determined using UV-Vis and the concentration of gold in the solution was quantified via ICP-Mass Spectroscopy. With these studies, the number of dye molecules per GS-AuNP were in the range from 2-20.
Synthesis of TAMRA conjugated GS-AuNPs (TG-AuNPs) was very straightforward. The inventors synthesized 815 nm emitting GS-AuNPs with a reported method before (Liu et al., 2013) and then incubated NHS-TAMRA with GS-AuNPs in phosphate buffered saline (PBS) solution in the dark at room temperature. The conjugation of TAMRA onto GS-AuNPs was first confirmed by agarose gel electrophoresis. As shown in
While AuNPs are known to partially quench fluorescence of organic dyes on their surface[9], fluorescence spectra of TG-AuNPs showed that dual-colored emissions were still observed and centered at 587 nm and 815 nm under 350 nm excitation, corresponding to the emissions of TAMRA dyes and GS-AuNPs, respectively (
While both monomeric TAMRA and GS-AuNPs are insensitive to pH changes from 6 to 10 (
To fundamentally understand the pH response mechanism of TAMRA on GS-AuNPs, the inventors further investigated UV-Vis absorption of TG-AuNPs at pH 6 and 10, respectively. As shown in
To further understand the origin of the pH effect on the dimerization of TAMRA on GS-AuNPs, the inventors measured the zeta potentials of TG-AuNPs at pH 10 and 6. As shown in
To investigate whether the observed reversible pH-dependent dimerization can be applied to pH sensitive dyes, the inventors conjugated 5(6)-carboxyfluorescein (
A much more sensitive pH-dependent emission was observed in FG-AuNPs. When pH is increased from 5 to 11, the 525 nm emission intensity of fluorescein on AuNPs under 470 nm excitation had increased about 19 times (
It should be noted that such pH-dependent emission is limited to ultrasmall AuNPs because the pH-dependent emission was no longer observed from TAMRA on the 7 nm TG-AuNPs surface even though TAMRA emission was still observed (
Not limited to glutathione coated luminescent gold nanoparticles, the similar strategy can also be used to conjugate organic dyes to luminescent gold nanoparticles coated by cysteine. For example, TAMRA conjugated cysteine coated luminescent AuNPs (Cys-AuNPs) also exhibit pH responsive emissions. Shown in
To further demonstrate that pH responses from organic dyes can be tuned by tuning other surface ligands, cysteine-glycine coated luminescent AuNPs (Cys-gly-AuNPs) and cysteine-glutamate coated luminescent AuNPs (Cys-glu-AuNPs) were also synthesized using the procedure reported before, followed by conjugating TAMRA onto these two AuNPs. Shown in
Combination of all the results presented above, we found that conjugation of organic dyes to ultrasmall luminescent AuNPs leads to a unique synergy that enables pH insensitive dyes to exhibit pH-dependent emission and pH sensitive dyes to become more sensitive to pH changes in a larger pH range. Therefore, the emission ratio of organic dyes and AuNPs can be used to quantitatively report the local pH changes. Such intriguing pH responses originate from the dimerization of organic dyes on the ultrasmall AuNP surface, of which geometries were found to be very sensitive to surface charges and can be modulated through the protonation of surrounding AuNP surface ligands. It should be noted that such pH-dependent emission is limited to ultrasmall AuNPs because the inventors no longer observed similar pH-dependent emission from TAMRA on the 7 nm TG-AuNPs surface even though TAMRA emission was still observed (
All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
Adachi et al., Ind. Eng. Chem. Res., 53, 13046-13057; 2014.
Chen et al., J. Am. Chem. Soc., 135, 11595-11602, 2013.
Chou and Chan, Adv. Healthcare. Mater., 1, 714-721, 2012.
Del Monte et al., Langmuir, 16, 7377-7382; 2000.
Dennis et al., ACS Nano, 6, 2917-2924; 2012.
Han and Burgess, Chem. Rev., 110, 2709-2728; 2009.
Hanson et al., Biol. Chem., 279, 13044-13053; 2004.
Hu and Gao, ACS Nano, 4, 6080-6086, 2010.
Kobayashi et al., Chem. Rev.,110, 2620-2640; 2010.
Kurishita et al., J. Am. Chem. Soc., 132, 13290-13299; 2010.
Liu et al., Angew. Chem.; 52, 12572-12576, 2013.
Ogawa et al., Acs Chemical Biology, 4, 535-546; 2009.
Ogawa et al., Mol. Biosyst., 6, 888-893; 2010.
Palner et al., Angew. Chem., 54, 11477-11480; 2015.
Valdesaguilera and Neckers, Accounts Chem. Res., 22, 171-177; 1989.
Wang et al., J. Am. Chem. Soc., 133, 2192-2197; 2011.
Wei et al., Analyst., 135, 1406-1410; 2010.
Xie et al., Biomaterials, 31, 3016-3022; 2010.
Yu and Zheng, ACS Nano, 9, 6655-6674; 2015.
Yu et al., Angew. Chem., 54, 15434-15438; 2015.
Yu et al., J. Am. Chem. Soc., 133, 11014-11017, 2011.
Zheng et al., J. Am. Chem. Soc., 125, 7780-7781; 2003.
Zheng et al., Annu. Rev. Phys. Chem., 58, 409-431, 2007.
Zheng et al., Nanoscale, 4, 4073, 2012.
Zheng et al., Phys. Rev. Lett., 93, 077402; 2004.
Zhou et al., Angew. Chem., 50, 3168-3172; 2011.
Zhou et al., Angew. Chem., 50, 6109-6114; 2011.
Zhou et al., Angew. Chem., 51, 10118-10122; 2012.
The present application claims the benefit of priority to U.S. Provisional Application Ser. No. 62/273,147, filed on Dec. 30, 2015, the entirety of which is incorporated herein by reference.
This invention was made with government support under Grant No. R01DK103363 awarded by the National Institutes of Health. The government has certain rights in the invention.
Number | Date | Country | |
---|---|---|---|
62273147 | Dec 2015 | US |